Delivery Order SPE2DB22D9353-SPE2DB25FX2FB
- Not listed
- The Defense Logistics Agency awarded a $1,547.40 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at approximately $500 million...
- The Defense Logistics Agency awarded a $38,685 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. This firm fixed-price delivery order, issued on September 17, 2025, with an ultimate completion date of October 8, 2025, represents a discrete purchase under the agency's broader pharmaceutical supply framework. The contract contains no set-aside designation, allowing...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $15,474 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes, with an ultimate completion date of October 8, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA under the SPE2DB...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The contract, valued at $27,907.20 with a firm fixed-price structure, is scheduled for completion by September 5, 2025, and was awarded on August 14, 2025. This delivery order carries no set-aside designation and leverages DMS Pharmaceutical Group's existing Indefinite...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $3,094.80 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the delivery at its Park Ridge location with an ultimate completion date of October 2, 2025. This delivery order was issued without a set-aside designation, leveraging the company's competitive capabilities...
- The Defense Logistics Agency awarded a delivery order valued at $13,926.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, issued on September 12, 2025, with an ultimate completion date of October 3, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The contract carries no...
- The Defense Logistics Agency awarded a delivery order valued at $10,273.38 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, issued on September 9, 2025, carries an ultimate completion date of September 30, 2025, with no set-aside designation applied. The contract represents a discrete fulfillment under DMS Pharmaceutical Group's...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $7,737 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of Xolair 75 mg/0.5 ml syringe 0.5 ml, with an ultimate completion date of October 30, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) awarded to DMS Pharmaceutical Group Inc. under the DLA's...
- The Defense Logistics Agency awarded a delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/ml syringes. This firm fixed-price delivery order, issued on September 10, 2025, is scheduled for ultimate completion by October 1, 2025, with performance taking place at the awardee's Park Ridge facility. The contract was awarded without a set-aside designation,...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $15,474.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 150 MG/ML syringes. The award, issued on September 16, 2025, with an ultimate completion date of October 7, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA...
- SPE2DB22D9353Indefinite Delivery Contract
- SPE2DB22D9353-SPE2DB25FX2FBDelivery Order
The Defense Logistics Agency awarded a $9,284.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 75 mg/0.5 mL syringes. The contract, issued on September 17, 2025, with an ultimate completion date of October 8, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $499.999 billion and valid through November 2026, which authorizes the agency to procure a comprehensive range of pharmaceutical products supporting military health facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently securing delivery orders from the Defense Logistics Agency for diverse medical products ranging from prescription medications to biologics and specialty pharmaceuticals. The company's core business involves distributing branded and generic prescription drugs, over-the-counter medications, and medical consumables directly to Department of Defense healthcare sites. This particular delivery order for Xolair, a monoclonal antibody used to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria, supports DLA's mission to ensure pharmaceutical availability for military medical facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.3k | 9/17/25 |